Zhitong Finance App News, Leadman (300289.SZ) issued an announcement. The company recently received a report from its subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) that the recombinant group B meningococcal vaccine (Escherichia coli) developed by Xiansheng Xiangrui obtained the “Drug Clinical Trial Approval Notice” from the China Drug Administration. The drug will conduct clinical trials to prevent epidemic encephalomyelitis caused by Neisserococcus meningitidis group B.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.